22:52 , Jan 15, 2019 |  BC Week In Review  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
23:49 , Jan 14, 2019 |  BC Extra  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
20:30 , Jan 4, 2019 |  BC Extra  |  Company News

Immunocore taps MedImmune's Jallal as CEO

TCR company Immunocore Ltd. (Abingdon, U.K.) hired Bahija Jallal as CEO. She was EVP of AstraZeneca plc (LSE:AZN; NYSE:AZN) and president of its MedImmune LLC subsidiary. Jallal, who joined MedImmune in 2006, oversaw the development...
18:56 , Nov 16, 2018 |  BC Week In Review  |  Company News

ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report . ICER said...
18:36 , Nov 9, 2018 |  BC Week In Review  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
23:40 , Nov 8, 2018 |  BC Extra  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...
17:57 , Sep 28, 2018 |  BC Week In Review  |  Company News

ICER finds asthma mAbs to be not cost-effective

In a draft evidence report , the Institute for Clinical and Economic Review (ICER) found that five biologics approved or in testing to treat asthma were not cost-effective compared with standard of care (SOC) therapies...
18:00 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it does not plan to submit regulatory applications for Fasenra benralizumab to treat chronic obstructive pulmonary disease (COPD) after the drug missed the primary endpoint of reducing exacerbations in a...
19:07 , May 30, 2018 |  BC Extra  |  Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it does not plan to submit regulatory applications for Fasenra benralizumab to treat chronic obstructive pulmonary disease after the drug missed the primary endpoint of reducing exacerbations in a second...